Trethera Corporation initiates a clinical trial for TRE-515, exploring its potential in oncology and autoimmune diseases ...

Anbogen Therapeutics gains FDA approval for ABT-301, initiating a pivotal trial for metastatic colorectal cancer, targeting ...

An expert discusses the transformative impact of CAR T-cell therapy in relapsed/refractory large B-cell lymphoma, ...

An expert discusses the selection of CAR T-cell therapies for third-line large B-cell lymphoma (LBCL), noting that while all ...

George Mulligan, PhD, discusses the ODAC's review of daratumumab for high-risk smoldering multiple myeloma, noting its efficacy in delaying progression but raising questions about patient criteria.

A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...

In this week's Targeted Pulse, we cover new FDA designations for cancer drugs, advances in targeted therapies, and key ...

The HIMALAYA study reveals the STRIDE regimen significantly improves 5-year survival rates in unresectable HCC, redefining ...

A groundbreaking trial explores personalized endocrine therapy for early-stage breast cancer, aiming to reduce chemotherapy's ...

A recent meta-analysis reveals no link between pathologic complete response and long-term survival in rectal cancer, ...

Cabozantinib and atezolizumab improve progression-free survival in metastatic prostate cancer, offering hope for high-risk ...

July marks a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment ...